Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.42 |
| ▸ | CA12 | O43570 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | CA9 | Q16790 | 5/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6984350 | 1.00 | CA2 (0.42) | CA2CA12CA1CA9CYP2D6 | |
| SCHEMBL1626250 | 1.00 | CA2 (0.42) | CA2CA12CA1CA9CYP2D6 | |
| SCHEMBL9911164 | 1.00 | CA2 (0.42) | CA2CA12CA1CA9CYP2D6 | |
| SCHEMBL16259947 | 1.00 | CA2 (0.42) | CA2CA12CA1CA9CYP2D6 | |
| SCHEMBL12150843 | 1.00 | CA2 (0.42) | CA2CA12CA1CA9CYP2D6 | |
| SCHEMBL1626249 | 1.00 | CA2 (0.42) | CA2CA12CA1CA9CYP2D6 | |
| SCHEMBL15948749 | 1.00 | CA2 (0.42) | CA2CA12CA1CA9CYP2D6 | |
| SCHEMBL1627640 | 1.00 | CA2 (0.42) | CA2CA12CA1CA9CYP2D6 | |
| SCHEMBL11540698 | 0.89 | CA2 (0.48) | CA2CA12CA1CA9CYP2D6 | |
| SCHEMBL20068297 | 0.89 | CA2 (0.48) | CA2CA12CA1CA9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110291095-B | Adenosine analogues and their use in regulating circadian clock | 北京生命科学研究所 | 2023-04-18 | — | — | CN | disclosed |
| US-20200397807-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | MITOPOWER LLC | 2020-12-24 | — | — | US | disclosed |
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2018-10-16 | — | — | US | disclosed |
| US-9676793-B2 | Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same | HOFFMANN-LAROCHE INC. (US) | 2017-06-13 | — | — | US | disclosed |
| WO-2016103166-A1 | CO-CRYSTALS OF 5-AMINO-2-OXOTHIAZOLO[4,5-D]PYRIMIDIN-3(2H)-YL-5-HYDROXYMETHYL TETRAHYDROFURAN-3-YL ACETATE AND METHODS FOR PREPARING AND USING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176899-A1 | CO-CRYSTALS OF 5-AMINO-2-OXOTHIAZOLO[4,5-D]PYRIMIDIN-3(2H)-YL-5-HYDROXYMETHYL TETRAHYDROFURAN-3-YL ACETATE AND METHODS FOR PREPARING AND USING THE SAME | HOFFMANN-LA ROCHE INC. | 2016-06-23 | — | — | US | disclosed |
| US-9227992-B2 | Method of preparing deoxyribofuranose compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140350231-A1 | METHOD OF PREPARING DEOXYRIBOFURANOSE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-8829168-B2 | Method of preparing deoxyribofuranose compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8829168-B2 | Method of preparing deoxyribofuranose compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| WO-2010057103-A1 | METHOD OF PREPARING DEOXYRIBOFURANOSE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20090197826-A1 | P-Toluene Sulfonic Acid Salt of 5-Amino-3-(2'-O-Acetyl-3'-Deoxy-Beta-D-Ribofuranosyl)-3H-Thiazole[4,5-d]pyrimidine-2-one and Methods for Preparation | ANADYS PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090197826-A1 | P-Toluene Sulfonic Acid Salt of 5-Amino-3-(2'-O-Acetyl-3'-Deoxy-Beta-D-Ribofuranosyl)-3H-Thiazole[4,5-d]pyrimidine-2-one and Methods for Preparation | ANADYS PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090197826-A1 | P-Toluene Sulfonic Acid Salt of 5-Amino-3-(2'-O-Acetyl-3'-Deoxy-Beta-D-Ribofuranosyl)-3H-Thiazole[4,5-d]pyrimidine-2-one and Methods for Preparation | ANADYS PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| EP-2076132-A1 | P-TOLUENE SULFONIC ACID SALT OF 5-AMINO-3-(2'-O-ACETYL-3'-DEOXY-BETA -D-RIBOFURANOSYL)-3H-THIAZOLE [4, 5-D]PYRIMIDINE-2-ONE AND METHODS FOR PREPARATION | Anadys Pharmaceuticals, Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008140549-A1 | P-TOLUENE SULFONIC ACID SALT OF 5-AMINO-3-(2'-O-ACETYL-3'-DEOXY-β-D-RIBOFURANOSYL)-3H-THIAZOLE [4, 5-D] PYRIMIDINE-2-ONE AND METHODS FOR PREPARATION | ANADYS PHARMACEUTICALS, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008140549-A1 | P-TOLUENE SULFONIC ACID SALT OF 5-AMINO-3-(2'-O-ACETYL-3'-DEOXY-β-D-RIBOFURANOSYL)-3H-THIAZOLE [4, 5-D] PYRIMIDINE-2-ONE AND METHODS FOR PREPARATION | ANADYS PHARMACEUTICALS, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| EP-1411954-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | Pharmasset Limited (BB) | 2004-04-28 | — | — | EP | disclosed |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | PHARMASSET, INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2002032920-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET LIMITED (BB) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397807-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | NADK, NNT, NAMPT | CA2 4723/4885CA12 4847/4885CA1 4880/4885 |
| US-20090197826-A1 | P-Toluene Sulfonic Acid Salt of 5-Amino-3-(2'-O-Acetyl-3'-Deoxy-Beta-D-Ribofuranosyl)-3H-Thiazole[4,5-d]pyrimidine-2-one and Methods for Preparation | DPYD, APRT, TYMS | CA2 1924/4885CA12 2841/4885CA1 2394/4885 |
| US-20160176899-A1 | CO-CRYSTALS OF 5-AMINO-2-OXOTHIAZOLO[4,5-D]PYRIMIDIN-3(2H)-YL-5-HYDROXYMETHYL TETRAHYDROFURAN-3-YL ACETATE AND METHODS FOR PREPARING AND USING THE SAME | SLC10A1, HCCS, HAVCR2 | CA2 3267/4885CA12 3293/4885CA1 4506/4885 |
| US-20140350231-A1 | METHOD OF PREPARING DEOXYRIBOFURANOSE COMPOUNDS | DUT, DPYD, DERA | CA2 4666/4885CA12 4161/4885CA1 4241/4885 |
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, SLC29A2, PNP | CA2 1911/4885CA12 2513/4885CA1 3469/4885 |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, PNP, SLC29A2 | CA2 1279/4885CA12 1506/4885CA1 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.